Efficacy and safety of up to two years of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis

Main Article Content

Tiffany Mayo
April Armstrong
Leon Kircik
Jonathan Silverberg
Andrew Blauvelt
Ben Esdaile
Shannon Schneider
Thomas Mark
Melinda Gooderham
Andrew Alexis


atopic dermatitis, tralokinumab


1. Weidinger S, Novak N. Lancet. 2016;387(10023):1109-1122.

2. Kaufman B, et al. Exp Dermatol 2018; 27: 340-357.

3. Blauvelt A, et al. J Am Acad Dermatol. 2022;S0190-9622(22)02345-3.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>